Several of these compounds are documented as complementary for repair because they hit different steps of the same process. TB-500 is paired in our graph with LL-37 (both drive angiogenesis and cell migration by distinct routes), with elafin (repair-signaling plus protease protection of healing tissue), with KPV (rebuilding tissue while quieting cytokines), with Matrixyl and Pal-GHK (systemic cell-migration support plus topical collagen-building), and with imunofan (structural repair plus immune modulation). Matrixyl and palmitoyl tripeptide-1 are both palmitoylated matrikines that raise collagen through non-identical routes and are considered additive, and both pair with elafin as matrix-building plus matrix-protecting. Elafin also complements LL-37 (enzyme-blocking plus microbe-killing), KPV and teduglutide (protease protection plus inflammation-calming or epithelial growth at mucosal surfaces). LL-37 and KPV are flagged as complementary but with caution, because LL-37 can be pro-inflammatory and cytotoxic at higher concentrations. Where pairs are marked complementary they converge on repair through different mechanisms rather than duplicating each other; several combinations are explicitly labeled speculative or only anecdotally supported.
LL-37 + KPV
Worth caution — see why below
Both have reported antimicrobial and immune-modulating activity but by different means: LL-37 is a cathelicidin that directly disrupts microbial membranes and neutralises endotoxin, while KPV calms the downstream inflammatory response via NF-κB. Together they cover microbial killing plus inflammation control, though LL-37 can be pro-inflammatory and cytotoxic at higher concentrations, so this is a nuanced pairing.
Not fully established
Both peptides' mechanisms clearly establish the claimed shared dimensions. KPV demonstrates anti-inflammatory effects via NF-κB suppression (IκBα stabilisation, IKK inhibition, p65RelA nuclear import blocking) and antimicrobial activity (S. aureus, C. albicans in vitro). LL-37 demonstrates innate immune activation through multiple TLR and FPR2 pathways, antimicrobial activity (broad-spectrum bacteria, fungi, viruses), and NF-κB signaling, while also showing anti-inflammatory capacity (endotoxin neutralization). The proposed relationship correctly identifies mechanistic complementarity: KPV acts primarily on downstream inflammatory resolution (NF-κB modulation), while LL-37 combines direct antimicrobial disruption with immune cell recruitment and endotoxin neutralization. The caveat about LL-37's pro-inflammatory and cytotoxic effects at higher concentrations is explicitly supported by the mechanism description ('pro- and anti-inflammatory', 'cytotoxicity to human cells at higher concentrations'). The explanation accurately reflects the distinct pathways and their potential synergy without overstating the relationship.
Matrixyl + Palmitoyl Tripeptide-1
May be complementary
Both are palmitoylated matrikine peptides that drive fibroblasts to make more collagen and rebuild the dermal matrix, but they come from different collagen fragments and hit the pathway somewhat differently (Matrixyl/Pal-KTTKS via a fibroblast matrikine/TGF-beta route; Pal-GHK via broad gene modulation and MMP suppression). Because they converge on the same skin-firming, wrinkle-reducing outcome through non-identical routes, they are frequently layered together in topical formulas and are considered additive rather than redundant.
Not fully established
The mechanisms clearly justify this complementary relationship. Both peptides are palmitoylated matrikine fragments (Pal-KTTKS and Pal-GHK) that target fibroblast surface receptors and TGF-beta signaling to stimulate collagen synthesis and dermal matrix production. The shared dimensions (collagen_synthesis, dermal_matrix, tissue_repair) are explicitly documented in both mechanisms. The explanation accurately reflects mechanistic differences: Matrixyl operates primarily through matrikine and TGF-beta signaling with MMP/plasmin inhibition, while Pal-GHK additionally engages integrin α2β1, Smad-dependent transcription, and broader anti-inflammatory effects (IL-6, TNF-α suppression). Both converge on collagen I/III synthesis and wrinkle reduction but through partially distinct pathways, supporting the 'complementary' classification rather than redundancy. The claim that they are 'additive rather than redundant' is consistent with their overlapping but non-identical mechanism profiles as documented.
Matrixyl + Elafin
May be complementary
Matrixyl stimulates collagen and ECM production while inhibiting matrix-degrading proteases; elafin adds antiprotease protection of elastin/collagen by blocking neutrophil elastase. Complementary matrix-building plus matrix-protecting actions in skin repair.
Not fully established
Both peptides' mechanisms clearly support complementary roles in dermal matrix maintenance and tissue repair. Elafin inhibits neutrophil elastase, proteinase 3, and cathepsin G—proteases that degrade collagen and elastin—providing matrix protection. Matrixyl stimulates collagen I/III/IV synthesis and inhibits MMPs and plasmin, providing matrix building and degradation prevention. The mechanisms establish distinct but complementary actions: Elafin protects existing matrix from serine protease degradation while Matrixyl actively synthesizes new matrix and inhibits other matrix-degrading pathways. Both peptides are tagged with dermal_matrix and tissue_repair, and their target mechanisms (antiprotease activity vs. anabolic ECM stimulation) directly support the claimed complementary relationship in skin repair contexts.
Palmitoyl Tripeptide-1 + Elafin
May be complementary
In a skin-matrix context these are complementary: palmitoyl tripeptide-1 (Pal-GHK) stimulates collagen/elastin synthesis and suppresses MMPs, while elafin protects the dermal matrix by inhibiting elastase and other proteases that degrade elastin. One builds the matrix, the other guards it from enzymatic breakdown.
Not fully established
The mechanisms clearly establish complementary roles in dermal matrix maintenance. Elafin inhibits neutrophil elastase, proteinase 3, cathepsin G, and endogenous vascular elastase—all proteases that degrade extracellular matrix components. Palmitoyl Tripeptide-1 stimulates collagen and elastin synthesis while suppressing MMP-1 and other matrix-degrading enzymes. Both peptides are tagged with anti_inflammatory, dermal_matrix, and tissue_repair. The proposed relationship accurately reflects their mechanistic complementarity: one actively synthesizes and protects matrix components (Pal-GHK via TGF-β pathway activation and MMP suppression), while the other protects existing matrix from protease degradation (Elafin via serine protease inhibition). This is a genuine functional complementarity supported by their distinct but synergistic mechanisms.
Teduglutide + Elafin
May be complementary
Teduglutide drives intestinal epithelial growth and barrier repair through the GLP-2 receptor, while elafin protects that same mucosa by neutralizing destructive proteases and calming inflammation. Different mechanisms both supporting gut mucosal integrity and repair.
Not fully established
Both peptides' mechanisms clearly support mucosal_repair and tissue_repair functions through distinct but complementary pathways. Elafin inhibits neutrophil serine proteases (elastase, proteinase 3) and modulates NF-κB/inflammatory signaling to protect mucosal tissue from enzymatic destruction. Teduglutide activates GLP-2 receptor signaling to promote intestinal epithelial growth, proliferation, and barrier function. The mechanisms describe non-overlapping approaches to the same tissue outcome: one protective/anti-degradative, one growth/regenerative. Both are explicitly tagged with mucosal_repair and tissue_repair in their approved tags, and the explanation accurately reflects how their distinct molecular mechanisms would work synergistically on intestinal mucosa.
TB-500 + Elafin
May be complementary
TB-500 promotes cell migration, angiogenesis and matrix remodeling for wound healing, while elafin protects healing tissue by inhibiting neutrophil proteases and suppressing NF-κB inflammation. Distinct mechanisms both favoring tissue repair.
Not fully established
Both peptides' mechanisms clearly support the proposed complementary relationship with the three shared dimensions. Elafin inhibits neutrophil elastase, proteinase 3, and cathepsin S while modulating NF-κB and providing tissue protection at mucosal surfaces. TB-500 promotes angiogenesis, cell migration, matrix remodeling, and suppresses NF-κB/TNF-α/IL-1β/IL-6. Both are tagged with tissue_repair, anti_inflammatory, and NF_kB_modulation. The explanation accurately reflects their distinct but synergistic mechanisms: elafin acts as a protease inhibitor preventing tissue destruction during inflammation, while TB-500 actively promotes healing through cytoskeletal dynamics and angiogenesis. These represent complementary approaches to tissue repair—one protective/anti-inflammatory, one regenerative—both converging on NF-κB modulation and inflammation resolution.
TB-500 + LL-37
May be complementary
Both promote wound healing, new blood-vessel growth (VEGF), and reduced inflammation, but through distinct mechanisms — LL-37 drives keratinocyte migration and angiogenesis via EGFR/FPR2, while TB-500 regulates actin/cytoskeletal dynamics and cell migration. This makes them a strong complementary tissue-repair pairing.
Not fully established
Both peptides' mechanisms clearly establish the four shared dimensions claimed. LL-37 explicitly targets EGFR, FPR2, and TLR pathways leading to angiogenesis, wound healing, and keratinocyte migration with VEGF/VEGFA signaling noted. TB-500 explicitly targets integrins and G-actin for cell migration, angiogenesis via VEGF, and tissue remodeling. Both show anti-inflammatory effects (LL-37 via NF-κB/TLR signaling; TB-500 via NF-κB suppression and reduced TNF-α/IL-1β/IL-6). Both list tissue_repair, angiogenesis, anti_inflammatory, and VEGF_upregulation in approved tags. The explanation correctly identifies distinct mechanistic pathways (LL-37: EGFR/FPR2/keratinocyte-driven; TB-500: actin/cytoskeletal/integrin-driven) that would complement rather than duplicate each other. The relationship type 'complementary' is well-justified by the mechanism material.
Elafin + LL-37
May be complementary
Both are human host-defense molecules but hit different targets: LL-37 is a cathelicidin that directly punctures microbial membranes, while elafin blocks the destructive enzymes (elastase, proteinase 3) that neutrophils release. Together they cover both direct killing and protection of the tissue from friendly-fire enzyme damage, converging on mucosal defense and repair.
Not fully established
The proposed relationship is well-justified by the mechanism material. Both peptides share the four claimed dimensions: (1) innate_immune—both are explicitly tagged and described as host-defense molecules with immune modulation roles; (2) antimicrobial—both have broad-spectrum antimicrobial activity documented; (3) anti_inflammatory—both are tagged and show anti-inflammatory effects; (4) tissue_repair—both are tagged with tissue repair/mucosal protection roles. The 'complementary' relationship type is strongly supported: the mechanisms show distinct but synergistic modes of action—LL-37 targets membrane receptors (FPR2, TLRs) and directly kills microbes, while elafin inhibits neutrophil serine proteases (elastase, proteinase 3) to prevent tissue damage. The explanation accurately reflects that they converge on mucosal defense through different mechanisms: direct antimicrobial activity versus protection from collateral enzyme damage. This is a textbook complementary relationship where both peptides address the same biological problem (mucosal defense) via non-overlapping mechanisms.
Elafin + KPV
May be complementary
Both dampen inflammation at mucosal surfaces largely by restraining NF-κB signaling, but by different means: KPV (an α-MSH fragment) suppresses inflammatory cytokines and stabilizes IκBα, while elafin blocks tissue-destroying proteases. In a gut/mucosal setting they address inflammation and barrier protection from complementary angles.
Not fully established
The mechanisms clearly establish complementary roles in mucosal inflammation control. Both peptides share three documented dimensions: (1) innate_immune function—elafin via protease inhibition and antimicrobial activity, KPV via immunomodulation and cytokine suppression; (2) anti_inflammatory effects—elafin through NF-κB modulation and tissue protection, KPV through TNF-α/IL-1β/IL-6 suppression; (3) NF-κB_modulation—elafin via NF-κB pathway modulation (src-17, src-23), KPV via IκBα stabilization and IKK complex inhibition. The explanation accurately characterizes their distinct mechanisms: KPV acts through cytokine suppression and IκBα stabilization, while elafin acts through protease inhibition and tissue protection. Both target mucosal barrier integrity and inflammation resolution in overlapping contexts (gut/mucosal surfaces), making them genuinely complementary rather than redundant. The proposed relationship type and shared dimensions are directly supported by the provided mechanism material.
Matrixyl + TB-500
No known conflict in the research
TB-500 supports the cell-migration and ECM-remodeling side of repair, while Matrixyl (a topical collagen matrikine) stimulates collagen I/III/IV and fibronectin production. They target different steps of matrix rebuilding \u2014 one systemic, one topical \u2014 so they complement rather than overlap.
Not fully established
The proposed complementary relationship is justified by the mechanism material. TB-500's mechanisms include integrin-mediated ECM remodeling, VEGF-driven angiogenesis, TGF-β signaling, and cell migration—processes that prepare tissue for and facilitate repair. Matrixyl's mechanisms focus specifically on collagen synthesis (types I, III, IV), fibronectin production, and matrix deposition—the structural rebuilding phase. The shared dimension 'tissue_repair' is explicitly present in both peptides' approved tags. The explanation correctly identifies that they address different sequential steps: TB-500 promotes the cellular and vascular environment for repair (migration, angiogenesis, remodeling signals), while Matrixyl directly stimulates the synthesis and deposition of structural matrix components. The distinction between systemic (TB-500) and topical (Matrixyl) mechanisms is supported by their respective target profiles and delivery contexts. This represents a genuine complementary relationship where both contribute to tissue repair through non-overlapping mechanisms.
Palmitoyl Tripeptide-1 + TB-500
No known conflict in the research
TB-500 (thymosin β4 fragment) promotes cell migration, angiogenesis and anti-inflammatory tissue repair, while Pal-GHK drives collagen and matrix deposition. They converge on the same goal of tissue healing through distinct pathways (actin/cytoskeletal remodeling vs TGF-β collagen synthesis), so they can be viewed as complementary for repair contexts.
Not fully established
Both peptides' mechanisms clearly establish the two claimed shared dimensions. (1) Anti-inflammatory: Palmitoyl Tripeptide-1 shows anti-inflammatory effects via IL-6 and TNF-α suppression (src-8, src-25); TB-500 shows anti-inflammatory effects via TNF-α, IL-1β, IL-6 reduction and NF-κB suppression. (2) Tissue_repair: Both are explicitly tagged and mechanistically described as promoting tissue repair—Pal-GHK through collagen/matrix synthesis and MMP modulation; TB-500 through cell migration, angiogenesis, and ECM remodeling. The explanation correctly identifies that they operate via distinct pathways (actin/cytoskeletal dynamics vs. TGF-β-driven collagen synthesis) while converging on tissue healing outcomes. This is a classic complementary relationship: non-overlapping mechanisms addressing the same functional goal. The proposed relationship type and shared dimensions are well-justified by the provided mechanism material.
Imunofan + TB-500
No known conflict in the research
TB-500 drives cytoskeletal-based cell migration, angiogenesis and NF-κB-suppressing anti-inflammatory repair. This converges with imunofan's reported fibroblast/keratinocyte stimulation and anti-inflammatory cytokine modulation through an entirely different mechanism, supporting a complementary tissue-recovery goal.
Not fully established
Both peptides' mechanisms clearly support the claimed shared dimensions. For tissue_repair: Imunofan explicitly stimulates fibroblast and keratinocyte proliferation and tissue repair; TB-500 drives angiogenesis, cell migration, and tissue/collagen matrix remodeling—distinct but convergent mechanisms. For anti_inflammatory: Imunofan reduces TNF and IL-6 through cytokine modulation; TB-500 reduces TNF-α, IL-1β, IL-6 via NF-κB suppression—again, different pathways achieving the same outcome. The explanation accurately characterizes these as mechanistically distinct (cytokine modulation vs. NF-κB suppression; thymopoietin signaling vs. actin/integrin dynamics) yet functionally complementary for tissue recovery, which is precisely what 'complementary' should mean. The mechanisms do not contradict this relationship.
Imunofan + Elafin
No known conflict in the research
Imunofan is a thymopoietin-based immunomodulator that boosts phagocytic/antimicrobial defenses and supports tissue repair, complementing elafin's antiprotease and antimicrobial actions. Different mechanisms supporting immune balance and mucosal repair.
Not fully established
Both peptides share the three claimed dimensions in their approved tags and mechanisms. Elafin targets neutrophil serine proteases and provides antimicrobial/tissue protection via protease inhibition and NF-κB modulation. Imunofan enhances phagocytic/bactericidal activity and tissue repair via thymopoietin receptor signaling and antioxidant pathways. Their mechanisms are distinct (protease inhibition vs. immune cell activation) yet both contribute to innate immunity, anti-inflammatory effects, and tissue repair. The 'complementary' relationship is justified: they operate through different pathways (Elafin: direct protease inhibition; Imunofan: immune cell enhancement and redox balance) to achieve overlapping functional outcomes in immune defense and tissue homeostasis.
Imunofan + LL-37
No known conflict in the research
Imunofan bidirectionally normalizes immune function, boosts phagocytosis/NK activity and antioxidant defenses, and supports tissue repair, while LL-37 adds direct antimicrobial and TLR-based innate actions. Different mechanisms converging on immune balance and repair.
Not fully established
Both peptides' mechanisms clearly support the three claimed shared dimensions. (1) Innate_immune: LL-37 targets FPR2, TLRs, and promotes NETs/chemotaxis; Imunofan enhances phagocytic/bactericidal activity and NK cytotoxicity. (2) Anti_inflammatory: LL-37 shows immunomodulation with both pro- and anti-inflammatory effects; Imunofan explicitly modulates anti-inflammatory cytokines (reduced TNF, IL-6). (3) Tissue_repair: LL-37 promotes angiogenesis, wound healing, and keratinocyte migration; Imunofan stimulates fibroblast and keratinocyte proliferation. The explanation accurately characterizes their complementary nature—LL-37 provides direct antimicrobial/TLR signaling while Imunofan provides bidirectional immune normalization and antioxidant support—with both converging on innate immunity, inflammation control, and tissue repair. The mechanisms justify this relationship type and all three shared dimensions.
Imunofan + KPV
No known conflict in the research
KPV is a potent NF-κB-suppressing anti-inflammatory (lowering TNF-α, IL-1β, IL-6) with mucosal/antimicrobial activity, working through a different mechanism than imunofan's thymic immunocorrection. Both push toward calmer inflammation and better mucosal defense, making them a plausible complementary anti-inflammatory pairing.
Not fully established
Both peptides' mechanisms clearly establish the two shared dimensions. (1) Innate_immune: Imunofan enhances phagocytic/bactericidal activity of neutrophils and macrophages, and NK cell cytotoxicity; KPV shows antimicrobial activity and mucosal barrier repair. (2) Anti_inflammatory: Imunofan modulates anti-inflammatory cytokines (reduced TNF, IL-6); KPV suppresses TNF-α, IL-1β, IL-6 via NF-κB inhibition. The explanation correctly identifies mechanistic distinction (thymic immunocorrection vs. NF-κB suppression) and complementarity is justified: they target inflammation through different pathways (Imunofan via thymopoietin/cAMP-PKA/Th1-Th2 balance; KPV via NF-κB/MAPK) while both reducing pro-inflammatory cytokines and supporting innate immunity. The proposed pairing is well-grounded in the provided mechanisms.
Teduglutide + LL-37
No known conflict in the research
Both support repair of epithelial/mucosal surfaces by different means: teduglutide promotes intestinal epithelial proliferation, while LL-37 drives keratinocyte/epithelial migration, wound closure and antimicrobial defense at mucosal barriers. They can reinforce barrier healing from separate pathways, though LL-37 can be cytotoxic at higher concentrations, so this is more speculative.
Not fully established
Both peptides' mechanisms clearly support tissue_repair through distinct but complementary pathways affecting epithelial/mucosal surfaces. Teduglutide explicitly promotes intestinal epithelial growth, proliferation, and mucosal repair via GLP-2 receptor signaling. LL-37 explicitly supports keratinocyte migration, wound healing, and angiogenesis via multiple pathways (FPR2, TLRs, EGFR transactivation, VEGF signaling). The proposed relationship correctly identifies that they work through different mechanisms (proliferation/growth vs. migration/wound closure/antimicrobial defense) on epithelial barriers. Both are tagged with tissue_repair. The caveat about LL-37's cytotoxicity at higher concentrations is appropriately noted in the explanation and does not contradict the complementary relationship at therapeutic concentrations. The mechanisms justify this as a supported complementary relationship.
Teduglutide + KPV
No known conflict in the research
Both target the gut lining but by entirely different routes: KPV calms mucosal inflammation (NF-κB suppression, reduced colitis severity in animal models), while teduglutide is a GLP-2 agonist that stimulates intestinal epithelial growth and repair. Pairing an inflammation-dampener with a growth/repair signal is a logically complementary approach to restoring a damaged gut barrier, though this combination is only anecdotally supported.
Not fully established
Both peptides' mechanisms clearly establish the shared dimension of gut_barrier_integrity through distinct pathways: KPV suppresses mucosal inflammation (NF-κB inhibition, reduced colitis severity, mucosal barrier repair in animal models) while teduglutide promotes epithelial growth, proliferation, and mucosal repair via GLP-2 receptor signaling. The proposed relationship as 'complementary' is justified—they address barrier integrity through mechanistically different routes (inflammation resolution vs. tissue growth/repair), which logically complement each other. The explanation accurately reflects both mechanisms' documented effects on the gut barrier, and the caveat about anecdotal support appropriately acknowledges the lack of direct clinical evidence for the combination.
Semax + LL-37
No known conflict in the research
Both support angiogenesis, tissue repair, and anti-inflammatory signaling, though Semax is oriented toward neuroprotection via BDNF/NGF-TrkB pathways and LL-37 toward peripheral wound healing via VEGF/EGFR. Overlap is modest and context-dependent rather than a targeted combination.
Not fully established
Both peptides' mechanisms support the three claimed shared dimensions: (1) tissue_repair: LL-37 explicitly promotes angiogenesis, wound healing, and keratinocyte migration; Semax shows BDNF/NGF upregulation and neuroprotection, both tissue-repair mechanisms. (2) angiogenesis: LL-37 directly targets VEGF/VEGFA signaling and angiogenesis; Semax is tagged with angiogenesis in approved tags. (3) anti_inflammatory: LL-37 shows immunomodulation and NF-κB signaling; Semax shows anti-inflammatory/immune modulation and NF-κB modulation. The explanation accurately characterizes the relationship as complementary rather than synergistic—different tissue contexts (peripheral vs. neural) and different primary pathways (VEGF/EGFR vs. BDNF/TrkB) but overlapping functional outcomes. The modest, context-dependent overlap described is consistent with the mechanisms provided.
Semax + KPV
No known conflict in the research
KPV is the C-terminal tripeptide of alpha-MSH (a melanocortin peptide) and Semax is an ACTH-derived melanocortin-family fragment; both exert anti-inflammatory effects and interact with the MMP-9 pathway. They act through different routes (KPV largely intracellular NF-kB suppression, Semax via neuro-immune modulation) but converge on dampening inflammation, making them plausibly complementary for anti-inflammatory goals.
Not fully established
The proposed relationship lacks support from the mechanism descriptions. While both peptides show anti-inflammatory effects and MMP-9 involvement, the explanation falsely characterizes their melanocortin family status and receptor interactions. Semax targets TrkB and μ-opioid receptors with proposed melanocortin antagonism/partial agonism, whereas KPV's melanocortin-1 receptor binding is explicitly 'contested/minority reports' and most sources show independence from melanocortin receptors. The mechanisms do not establish a shared 'melanocortin-family' basis. Additionally, no 'shared dimensions' are claimed, yet the explanation asserts convergence on inflammation suppression—but this convergence is not explicitly supported by the provided mechanism material; it describes different pathways (neuro-immune modulation vs. intracellular NF-kB) without demonstrating mechanistic complementarity or synergy. The relationship is plausible in principle but not justified by the given mechanism descriptions alone.
TB-500 + KPV
No known conflict in the research
KPV dampens the inflammatory cytokine signal (TNF-α, IL-6, NF-κB), while TB-500 drives the structural side of repair through actin/cytoskeletal dynamics, angiogenesis and cell migration. One quiets inflammation, the other rebuilds tissue — a complementary pairing for wound and mucosal healing.
Not fully established
Both peptides' mechanisms clearly establish the three claimed shared dimensions: (1) inflammation_resolution and anti_inflammatory effects are documented for both (KPV suppresses TNF-α, IL-1β, IL-6, COX-2; TB-500 reduces TNF-α, IL-1β, IL-6); (2) NF-κB modulation is explicitly present in both (KPV via IκBα stabilization and p65RelA nuclear import inhibition; TB-500 via NF-κB suppression). The complementary relationship is well-justified: KPV's mechanism targets inflammatory signaling pathways (NF-κB, MAPK, pyroptosis), while TB-500's mechanism addresses tissue reconstruction through G-actin sequestration, integrin-mediated ECM remodeling, angiogenesis (VEGF), and survival pathways (PI3K/Akt). The explanation accurately reflects that one peptide dampens inflammatory signals while the other drives structural repair—a genuine complementary pairing supported by their distinct but non-overlapping mechanistic profiles.
Matrixyl + Imunofan
No documented interaction in our data — that is not a safety clearance.
Matrixyl + Teduglutide
No documented interaction in our data — that is not a safety clearance.
Matrixyl + Semax
No documented interaction in our data — that is not a safety clearance.
Matrixyl + LL-37
No documented interaction in our data — that is not a safety clearance.
Matrixyl + KPV
No documented interaction in our data — that is not a safety clearance.
Palmitoyl Tripeptide-1 + Imunofan
No documented interaction in our data — that is not a safety clearance.
Palmitoyl Tripeptide-1 + Teduglutide
No documented interaction in our data — that is not a safety clearance.
Palmitoyl Tripeptide-1 + Semax
No documented interaction in our data — that is not a safety clearance.
Palmitoyl Tripeptide-1 + LL-37
No documented interaction in our data — that is not a safety clearance.
Palmitoyl Tripeptide-1 + KPV
No documented interaction in our data — that is not a safety clearance.
Imunofan + Teduglutide
No documented interaction in our data — that is not a safety clearance.
Imunofan + Semax
No documented interaction in our data — that is not a safety clearance.
Teduglutide + Semax
No documented interaction in our data — that is not a safety clearance.
Teduglutide + TB-500
No documented interaction in our data — that is not a safety clearance.
Semax + TB-500
No documented interaction in our data — that is not a safety clearance.
Semax + Elafin
No documented interaction in our data — that is not a safety clearance.